NO953883L - Rensing av faktor VII - Google Patents

Rensing av faktor VII

Info

Publication number
NO953883L
NO953883L NO953883A NO953883A NO953883L NO 953883 L NO953883 L NO 953883L NO 953883 A NO953883 A NO 953883A NO 953883 A NO953883 A NO 953883A NO 953883 L NO953883 L NO 953883L
Authority
NO
Norway
Prior art keywords
purification
factor vii
purification steps
fvi1
degradation
Prior art date
Application number
NO953883A
Other languages
English (en)
Norwegian (no)
Other versions
NO953883D0 (no
Inventor
Tony Joergensen
Anders H Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO953883D0 publication Critical patent/NO953883D0/no
Publication of NO953883L publication Critical patent/NO953883L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
NO953883A 1993-03-31 1995-09-29 Rensing av faktor VII NO953883L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner
PCT/DK1994/000122 WO1994022905A1 (en) 1993-03-31 1994-03-24 Purification of factor vii

Publications (2)

Publication Number Publication Date
NO953883D0 NO953883D0 (no) 1995-09-29
NO953883L true NO953883L (no) 1995-11-28

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953883A NO953883L (no) 1993-03-31 1995-09-29 Rensing av faktor VII

Country Status (16)

Country Link
US (1) US5700914A (enExample)
EP (1) EP0691984A1 (enExample)
JP (1) JPH08508264A (enExample)
CN (1) CN1039231C (enExample)
AU (1) AU677309B2 (enExample)
CA (1) CA2159313A1 (enExample)
CZ (1) CZ253395A3 (enExample)
DK (1) DK38293D0 (enExample)
FI (1) FI954649A0 (enExample)
HU (1) HUT72712A (enExample)
IL (1) IL109164A0 (enExample)
NO (1) NO953883L (enExample)
PL (1) PL310887A1 (enExample)
TW (1) TW278079B (enExample)
WO (1) WO1994022905A1 (enExample)
ZA (1) ZA941956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SI1308455T1 (sl) † 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2519020A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
DE602004025100D1 (de) * 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005054275A2 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor vii solutions to remove virus
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
AU2005318106B2 (en) * 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
DE602006015907D1 (de) * 2005-01-14 2010-09-16 Bayer Healthcare Llc Verfahren zur reinigung von factor vii
EP1907540B1 (en) * 2005-07-22 2012-12-19 Bayer HealthCare LLC In-solution activation of factor vii
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
BR112015008666B1 (pt) 2012-10-17 2020-04-07 Procter & Gamble produto extensível para tratamento dental e método de aplicação de um ativo para tratamento bucal
US11059857B2 (en) 2016-12-22 2021-07-13 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
HU9502846D0 (en) 1995-12-28
NO953883D0 (no) 1995-09-29
AU6423994A (en) 1994-10-24
CN1039231C (zh) 1998-07-22
PL310887A1 (en) 1996-01-08
CZ253395A3 (en) 1996-01-17
US5700914A (en) 1997-12-23
HUT72712A (en) 1996-05-28
TW278079B (enExample) 1996-06-11
ZA941956B (en) 1994-09-30
FI954649A7 (fi) 1995-09-29
IL109164A0 (en) 1994-06-24
FI954649L (fi) 1995-09-29
FI954649A0 (fi) 1995-09-29
CA2159313A1 (en) 1994-10-13
WO1994022905A1 (en) 1994-10-13
AU677309B2 (en) 1997-04-17
JPH08508264A (ja) 1996-09-03
CN1121723A (zh) 1996-05-01
EP0691984A1 (en) 1996-01-17
DK38293D0 (da) 1993-03-31

Similar Documents

Publication Publication Date Title
NO953883L (no) Rensing av faktor VII
GB2270030B (en) Method of producing fibre or film
DE69426278D1 (de) Kontinuierliche Herstellung eines Schlammes mit mehreren Komponenten
PL310550A1 (en) Fibre treating method
AU6430794A (en) A method of treating endo-osteal materials
ZA945657B (en) Method to inhibit restenosis
FI940865L (fi) Fermentointilaitos
FI944443A0 (fi) Menetelmä kaasun syöttämiseksi nesteeseen
DE69433831D1 (de) Modifizierung von Pertussistoxin
FI961431L (fi) Prosessi II
FI932871L (fi) Stereoselektiv anjonglykosylationsprocess
DE69318527D1 (de) Entwicklungsverfahren
DE69406974D1 (de) Beschichtungsverfahren
AU7687891A (en) Method for treating mechanical pulp plant effluent
AU5682790A (en) Method of treating tinea
NO810367L (no) Midler og prosess for beskyttelse av tre og belegg mot mikroorganismer.
FR2708210B1 (fr) Procédé de traitement d'un milieu poreux obstrué.
FI933530L (fi) Anordning foer tvinning av tvinningselement i vaexlande riktning
TW288066B (enExample)
AU7318691A (en) A method of treating a mammal with a biologically active compound
DE69408925D1 (de) Beschichtungsverfahren
FI945440L (fi) Prosessilaitos
FR2687403B1 (fr) Procede de fabrication d'un ester d'un compose organosilane et utilisation.
DK0587480T3 (da) Deponeringsindretning
EP0752856A4 (en) METHOD FOR TREATING HYPERLIPIDEMIA